Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANSEROVAX: COVID-19 Vaccine Response in Cancer Patients
NCT04935528Completed
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jun 2021
- Primary completion
- Jan 2022
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Centre Georges-François Leclerc. Primary endpoint: Seroprevalence of SARS-CoV-2 and ELISPOT at 1 year. Started Jun 2021; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04935528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935528.